Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
1.050
+0.040 (3.96%)
At close: Nov 22, 2024, 4:00 PM
1.100
+0.050 (4.75%)
After-hours: Nov 22, 2024, 4:11 PM EST
Nektar Therapeutics Employees
Nektar Therapeutics had 137 employees as of December 31, 2023. The number of employees decreased by 79 or -36.57% compared to the previous year.
Employees
137
Change (1Y)
-79
Growth (1Y)
-36.57%
Revenue / Employee
$679,832
Profits / Employee
-$1,228,474
Market Cap
193.68M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Accuray | 987 |
ADC Therapeutics | 274 |
Cellectis | 221 |
Sight Sciences | 214 |
BrainsWay | 134 |
Senseonics Holdings | 132 |
MediWound | 100 |
Inozyme Pharma | 59 |
NKTR News
- 4 days ago - Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence - PRNewsWire
- 8 days ago - Multiple Catalysts Ahead For Nektar Therapeutics - Seeking Alpha
- 15 days ago - Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Nektar Therapeutics Reports Third Quarter 2024 Financial Results - PRNewsWire
- 15 days ago - Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting - PRNewsWire
- 16 days ago - Nektar Therapeutics to Participate in Upcoming Investor Conferences - PRNewsWire
- 18 days ago - Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential - Benzinga
- 18 days ago - Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama - PRNewsWire